Climb Bio reports CLYM116 preclinical data showing >70% IgA reduction and longer half-life vs sibeprenlimab

Climb Bio, Inc.

In nonhuman primate study, CLYM116 showed ~2-3 times longer half-life and deeper IgA reduction vs sibeprenlimab at 6 mg/kg.
Subcutaneous CLYM116 demonstrated ~85% bioavailability and favorable tolerability in the NHP study.
CLYM116 Phase 1 trial in healthy volunteers expected to start Q4 2025 with initial data mid-2026.
CLYM116 is the only known 'sweeper' anti-APRIL monoclonal antibody in development for IgA nephropathy.
Updated KDIGO 2025 guideline highlights need for more active IgAN management, expanding potential market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.